Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Total Current Liabilities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Total Current Liabilities for 7 consecutive years, with $83.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 22.79% to $83.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.2 million, a 22.79% increase, with the full-year FY2025 number at $83.2 million, up 22.79% from a year prior.
  • Total Current Liabilities was $83.2 million for Q4 2025 at Kymera Therapeutics, up from $71.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $110.1 million in Q1 2021 to a low of $54.6 million in Q2 2023.
  • A 5-year average of $78.2 million and a median of $77.4 million in 2025 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 37.6% in 2023, then skyrocketed 40.87% in 2025.
  • Kymera Therapeutics' Total Current Liabilities stood at $92.5 million in 2021, then fell by 22.91% to $71.3 million in 2022, then grew by 20.11% to $85.7 million in 2023, then decreased by 20.92% to $67.8 million in 2024, then increased by 22.79% to $83.2 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Total Current Liabilities are $83.2 million (Q4 2025), $71.6 million (Q3 2025), and $87.5 million (Q2 2025).